Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026

About this update from Artelo Biosciences, Inc.

First-in-Human Results Demonstrate Favorable Safety and Pharmacokinetics Profile AI Aided Target Engagement Research Advancing Development of Novel Biomarkers SOLANA BEACH, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced two presentations of clinical and translational research findings supporting the development of ART26.12, the Company's proprietary selective fatty acid binding protein 5 (FABP5) inhibitor, at the International Cannabinoid Research Society (ICRS) 2026 Annual Symposium. The presentations include results from the Phase 1 clinical study of ART26.12 as well as new biomarker analyses designed to identify indicators of target engagement and pharmacological activity in healthy volunteers. During the first of two presentations, Professor Saoirse E. O'Sullivan, Vice President of Translational Science at Artelo Biosciences, shared results from the first-in-human study with a selective FABP5 inhibitor titled: A Phase 1 Study to Assess the Safety and Pharmacokinetics of ART26.12. The Phase 1 study evaluated single ascending oral doses of ART26.12 in healthy volunteers which demonstrated that ART26.12 was generally well-tolerated across all evaluated dose levels and exhibited predictable, linear pharmacokinetics. Key findings included: "Successfully advancing ART26.12 through its initial clinical testing marks a significant achievement for Artelo and validates years of foundational research focused on FABP5 biology," said Professor Saoirse E. O'Sullivan. "The favorable safety and pharmacokinetic profiles support continued clinical development of this novel therapeutic approach." Also today, Myles Osborn, Lead Medicinal Chemist at Artelo Biosciences, delivered new data in a presentation titled: Unbiased Identification of Putative Clinical Biomarkers of Target Engagement with the Selective Fatty Acid Binding Protein 5 Inhibitor ART26.12. Researchers interrogated proteomic and lipidomic databases from preclinical studies with ART26.12 with plasma samples collected from healthy volunteers who participated in the single ascending dose Phase 1 study of ART26.12 to identify potential biomarkers. Aided by art...

View stock analysis, news, and events for Artelo Biosciences, Inc.